A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis
Latest Information Update: 14 Jan 2022
At a glance
- Drugs Cilofexor (Primary)
- Indications Primary sclerosing cholangitis
- Focus Adverse reactions
- Acronyms PSC-Phase 2
- Sponsors Gilead Sciences
- 15 Nov 2021 Results assessing the serum IL-31 as a putative biomarker of pruritus in clinical trials of an FXR agonist in patients with NASH, PSC, and PBC, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 15 Nov 2021 Results of a safety and preliminary efficacy of CILO in a 96-week, open-label extension part presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
- 09 Nov 2021 According to a Gilead Sciences media release, data from this study will be presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting.